Her2 Status And Prediction Of Extended Endocrine Benefit With Breast Cancer Index (Bci) In Hr Plus Patients In The Adjuvant Tamoxifen: To Offer More? (Attom) Trial.

John Bartlett,Dennis C. Sgroi,Kai Treuner,Yi Zhang,Tammy Piper,Ranelle C. Salunga,Ikhlaaq Ahmed,Lucy Doos,Sarah Thornber,Karen J. Taylor,Elena F. Brachtel,Sarah Pirrie,Catherine A. Schnabel,Daniel William Rea

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 4|浏览59

暂无评分

摘要

522Background: BCI is a validated gene expression-based assay that stratifies patients based on risk of overall (0-10y) and late (post-5y) distant recurrence (DR) and predicts likelihood of benefit...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要